Moleculin Biotech is trading 6.88% up at $0.46 after the August 10, 2026 regular session closed at $0.43, with the move appearing linked to lingering enthusiasm over July 31 interim MIRACLE trial results showing higher remission rates for Annamycin combinations than control treatment.
- Investors are also weighing a recently priced $9.3 million public offering.
- The offering involves substantial share and warrant issuance, creating dilution concerns.